Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
Want to see ACRS full AI Analyst Report?
ACRS Stock Chart & Stats
$4.25
-$0.03(-1.20%)
At close: 4:00 PM EST
$4.25
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$1.34 - $5.15
Previous CloseN/A
Volume227.82K
Average Volume (3M)1.11M
Market Cap
$635.47M
Enterprise Value$522.03M
Total Cash (Recent Filing)$105.42M
Total Debt (Recent Filing)$1.99M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 12, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding139,663,680
10 Day Avg. Volume1,094,755
30 Day Avg. Volume1,106,653
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue62.39
Enterprise Value/Gross Profit81.73
Enterprise Value/Ebitda-7.14
Forecast
1Y Price Target
$10.38Price Target Upside144.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$5.71M
Bulls Say, Bears Say
Bulls Say
Bosakitug Clinical MilestoneBosakitug's completed Phase 2 enrollment and its long natural half-life that supports durable TSLP inhibition represent a clear proof-of-concept opportunity for the ATI-052 platform.
Long-acting Bispecific DesignATI-052's long effective half-life and bispecific, biparatopic design may enable convenient quarterly dosing while potentially delivering superior efficacy compared with competing antibody constructs.
Pipeline Breadth And Commercial OpportunityAclaris's mix of advancing ITK inhibitor programs and bispecific biologics, coupled with a limited set of branded treatments for atopic dermatitis, creates multiple potential value-inflection points and a sizeable commercial runway if clinical data are positive.
Bears Say
Clinical Outcome UncertaintyAbsence of human efficacy and safety data for ATI-052 and bosakitug means trial results could disappoint and materially depress the stock if outcomes are unfavorable.
Development And Approval RiskKey risks include potential trial delays, failed approvals, clinical setbacks across pipeline candidates, weaker-than-expected uptake, and the possibility of long-term shareholder dilution.
Preclinical Evidence And Disclosure ConcernsHeavy reliance on animal-model data and disclosed business relationships by the covering firm increase uncertainty about translatability to humans and may reduce confidence in the supporting research.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.34 and its highest was $5.15 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $635.47M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 73 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.008.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 139,663,680 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -1.414%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.38 (144.12% Upside)
$10.38 (144.12% Upside)
Hedge Fund Trend
Increased
By 7.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 9.4%
Last 30 Days ▼ 9.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.39%
12-Months-Change
Fundamentals
Return on Equity
-55.89%
Trailing 12-Months
Asset Growth
0.32%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$10.38
▲(144.12% Upside)
Technical Analysis
Ownership Overview
12.34% Insiders
7.41% Mutual Funds
48.90% Other Institutional Investors
20.60% Public Companies and
Individual Investors